Business Wire
28 Feb 2026, 00:00 UTC · 27w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
2 claims · each scored for market impact
IDEAYA Biosciences has dosed the first patient in the Phase 1 clinical trial of IDE034, a B7H3/PTK7 bispecific TOP1 ADC. — The commencement of a Phase 1 trial is a positive milestone for drug development pipelines, though early-stage trials carry high risk.
+0.30Biocytogen Pharmaceuticals is the partner involved in the development and potential commercialization of IDE034. — Partnership progress on a novel ADC candidate provides a catalyst for Biocytogen's valuation based on future royalty or milestone potential.
+0.20Which stocks this story touches
The company has reached a key clinical milestone by dosing the first patient in its Phase 1 trial of IDE034.
Continue reading
5 related stories
Search tags
The company's partner has successfully dosed the first patient in a clinical trial for a drug developed using their technology.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1d ago
